Hemab Therapeutics (COAG) Registration filing summary

Management team and governance

• COO services provided by Ancora Global Advisory AG, with Anant Murthy appointed as Chief Operating Officer effective September 1, 2025.

• Executive reports directly to the CEO and is subject to a four-month probation period.

• Compensation includes CHF 442,478 annual base salary, 40% target bonus, sign-on bonuses, equity participation, and benefit allowance.

• Executive eligible for 0.8% equity grant and five weeks paid vacation per year.

• Ancora responsible for Swiss employment law compliance, payroll, and benefits administration; Hemab retains responsibility for executive's performance.

Risk factors and disclosures

• Indemnification agreements in place for directors and officers, with limitations as per Delaware law.

• General liability insurance covers directors and officers for acts or omissions in their roles.

• Underwriting agreement provides for indemnification by underwriters against certain liabilities.

• SEC notes that some indemnification provisions may be unenforceable as contrary to public policy.

Offering details and pricing

• Estimated offering expenses total $5,750,000, including legal, accounting, and listing fees.

• Securities to be offered as soon as practicable after registration statement effectiveness.

• Recent equity grants include 306,900 stock options at IPO price, effective upon pricing.